Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in <i>IDH</i> -mutated newly diagnosed grade 3 astrocytoma (VORTEX).
Authors
Jeffrey Scott Wefel (ORCID: https://orcid.org/0000-0003-3584-023X)
Julie J. Miller (ORCID: https://orcid.org/0000-0002-1288-593X)
Sani H. Kizilbash (ORCID: https://orcid.org/0000-0001-8568-1519)
Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in IDH -mutated newly diagnosed grade 3 astrocytoma (VORTEX).
Jeffrey Scott Wefel, Julie J. Miller, Sani H. Kizilbash, E. Galanis et al.
Journal
Journal of Clinical Oncology
Topics
Glioma Diagnosis and Treatment
article
Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in IDH -mutated newly diagnosed grade 3 astrocytoma (VORTEX).
Jeffrey Scott Wefel, Julie J. Miller, Sani H. Kizilbash, E. Galanis, P. Kumthekar, Christine Lu‐Emerson, Ugonma Nnenna Chukwueke, Timothy J. Kaufmann, B. Ellingson, Daniel M. Trifiletti, Claire Yee, Rifaquat Rahman, Rachael A. Vaubel, Patrick Y. Wen, Ashlee Loughan, Amylou C. Dueck, Susan Michelle Geyer
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 44(16_suppl)
Institutions
Brigham and Women's Hospital (US), Mayo Clinic (US), Maine Medical Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), University of California, Los Angeles (US), Virginia Commonwealth University (US), Alliance for Clinical Trials in Oncology (US), WinnMed (US), University of Chicago (US), Massachusetts General Hospital (US), Dana-Farber Cancer Institute (US), Mayo Clinic in Arizona (US), Alliance Data (United States) (US), Mayo Clinic Hospital (US), Mayo Clinic in Florida (US), Dana-Farber Brigham Cancer Center (US)